Pharmaceuticals | Free Full-Text | The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
移植非適応での多発性骨髄腫に対するRVD lite(A Phase 2 Study of Modified Lenalidomide, Bortezomib and Dexamethasone in Transplant-Ineligible Multiple Myeloma ) - はくいのてんしちゃん論文編
Managing A Case of Newly-Diagnosed Transplant-Ineligible MM
How I manage frontline transplant-ineligible multiple myeloma
Combination Regimens for Multiple Myeloma Show Efficacy in the Transplant-Ineligible Population, According to Dingli
VRd Lite 療法
The efficacy and safety of modified bortezomib‐lenalidomide‐dexamethasone in transplant‐eligible patients with newly diagnosed multiple myeloma - Okazuka - 2020 - European Journal of Haematology - Wiley Online Library
Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis | SpringerLink
Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review - McCaughan - 2022 - British Journal of Haematology - Wiley Online Library
VA Committee
Multiple Myeloma Treatment Options | First Line Therapy
Tip Card: The VRd Regimen by International Myeloma Foundation - Issuu
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone - ScienceDirect
Current approaches to management of newly diagnosed multiple myeloma - Goel - 2022 - American Journal of Hematology - Wiley Online Library
Expert Guidance on Current Standards and New Directions in Newly Diagnosed Multiple Myeloma
SWOG - S2209- VRD-Lite Vs DRd-R Vs DRd-DR - Multiple Myeloma Clinical Trials
Frontline Therapy in Multiple Myeloma
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. - Abstract - Europe PMC
Developments in Newly Diagnosed Multiple Myeloma: Considerations for Improved Patient Outcomes
Understanding the VRd Regimen for Newly Diagnosed Myeloma by International Myeloma Foundation - Issuu
Treatment Considerations for Transplant-Ineligible Multiple Myeloma
Cancers | Free Full-Text | 30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma
